Pharmacists: Salè H-1B
Klasifikasyon Okipasyonèl Estanda 29-1051. 1,524 aplikasyon kondisyon travay; salè baz medyàn ofri $134,680, mwatye mitan $119,000–$146,827.
Demann (LCA)1,524
Salè medyan ofri$134,680
Mwatye salè yo$119,000–$146,827
10yèm–90yèm pousantaj$104,000–$159,432
Pa nivo salè
| Nivo revni | LCA | Salè medyan |
|---|---|---|
| Nivo I (antre) | 490 | $120,050 |
| Nivo II (kalifye) | 573 | $133,120 |
| Nivo III (eksperyans) | 238 | $142,628 |
| Nivo IV (plen kompetans) | 96 | $153,920 |
Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.
Anplwayè yo
Vil yo
Tit travay
- Pharmacist459
- Staff Pharmacist200
- Staff Pharmacist FT199
- Pharmacy Manager155
- Pharmacist-in-Charge89
- Clinical Pharmacist34
- Graduate Pharmacist Intern30
- CA Pharmacy Manager24
- CA Staff Pharmacist FT24
- Pharmacy Clinical Specialist10
- Foreign Pharmacy Graduate - International Pharmacy Intern10
- Foreign Pharmacy Graduate - International Pharmacy9
- Pharmacist - Sr.8
- Pharmacists8
- Supervising Pharmacist7
- Pharmacy Operations Supervisor7
- Clinical Staff Pharmacist6
- Pharmacist Manager6
- Pharmacy Resident6
- Staff Pharmacist FT, PMEL6
- Inpatient Clinical Pharmacist III5
- Retail Pharmacist5
- District Support Pharmacist FT5
- CA Staff Pharmacist Floater FT4
- Pharmacy Manager (Pharmacist-in-Charge)4
- Licensed Pharmacist4
- Rx Mgr Emerging Leader, CA4
- Pharmacist Intern4
- Pharmacist 14
- Pharmacist I4
Pa ane fiskal
| Ane fiskal | LCA | Salè medyan |
|---|---|---|
| FY2023 | 354 | $124,800 |
| FY2024 | 334 | $131,040 |
| FY2025 | 440 | $134,368 |
| FY2026 | 396 | $141,428 |
Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).